Abstract
Progressive familial intrahepatic cholestasis (PFIC) is a rare group of genetic disorders that typically present in infants and children, often progressing to end-stage liver disease. Using whole genome sequencing (WGS) for diagnosis, we aimed to assess phenotypic features and outcomes, in Pakistani children with different types of PFIC. The study included 116 pediatric participants with five PFIC types: PFIC1, ATP8B1 gene (n=19); PFIC2, ABCB11 (n=28); PFIC3, ABCB4 (n=52); PFIC4 TJP2 (n=15); and PFIC5 NR1H4 (n=2). Seventy unique variants were identified across the five genes. Age at genetic diagnosis was higher in PFIC3 patients. Clinical and laboratory findings showed significant overlap among all PFIC types. PFIC3 had a less aggressive course and better survival outcomes compared to PFIC1, PFIC2, and PFIC4. The cumulative survival rate was significantly higher at 89% (95% CI 43-98%) for patients who underwent liver transplantation, compared to 9% (95% CI 1-29%) for those who did not (p=0.016). The study provides the first comprehensive analysis of PFIC in Pakistani children, highlighting significant clinical overlap and the critical need for early genetic diagnosis using WGS. The findings underscore the importance of personalized treatment approaches, including early consideration for liver transplantation, to improve patient outcomes.
Competing Interest Statement
Aliaksandr Skrahin, Arndt Rolfs, Ahmad Malik and Volha Skrahina declared employment in a rare disease consulting company.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Rostock University (Germany), A2022-0072, 25.04 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.